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Objective. The latest European guidelines for the management of hemorrhagic shock suggest the use of vasopressors (nore-
pinephrine) in order to restore an adequate mean arterial pressure when fluid resuscitation therapy fails to restore blood pressure.
The administration of arginine vasopressin (AVP), or its analogue terlipressin, has been proposed as an alternative treatment in
the early stages of hypovolemic shock. Design. A meta-analysis of randomized controlled animal trials. Participants. A total of 433
animals from 15 studies were included. Interventions.The ability of AVP and terlipressin to reduce mortality when compared with
fluid resuscitation therapy, other vasopressors (norepinephrine or epinephrine), or placebo was investigated. Measurements and
Main Results. Pooled estimates showed that AVP and terlipressin consistently and significantly improve survival in hemorrhagic
shock (mortality: 26/174 (15%) in the AVP group versus 164/259 (63%) in the control arms; OR = 0.09; 95% CI 0.05 to 0.15; 𝑃 for
effect < 0.001; 𝑃 for heterogeneity = 0.30; 𝐼
2
= 14%). Conclusions. Results suggest that AVP and terlipressin improve survival in the
early phases of animal models of hemorrhagic shock. Vasopressin seems to be more effective than all other treatments, including
other vasopressor drugs. These results need to be confirmed by human clinical trials.
1. Introduction
Trauma is the principal cause of death for people under 35
years of age, with more than 5 million injury-related deaths
every year in the world. Approximately 30% of these deaths
can be attributed to hemorrhagic shock [1, 2]. Untreated
prehospital hemorrhagic shock is one of the leading causes of
cardiac arrest [3, 4]. Appropriate management and treatment
are necessary to prevent adverse events and outcomes [5–7].
The early phase of hemorrhagic shock is characterized by a
vasoconstrictive response and if the shock is left untreated it
can lead to vasodilation that does not respond to conventional
resuscitation strategies [8, 9]. Prehospital hemorrhagic shock
treatment should be focused on maintaining adequate mean
arterial pressure (MAP) along with organ perfusion up until
arrival at the hospital [10, 11].
Small volume resuscitation with colloids or hyperoncotic
fluids may be useful during early phases of uncontrolled
bleeding [12–14]. Recent international guidelines suggest
that vasopressors may also be required to maintain tissue
perfusion where fluid resuscitation itself does not achieve the
expected goal [15].
Arginine vasopressin (AVP) is an endogenous neuro-
hypophysial hormone with an antidiuretic function. The
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most important AVP release stimulus is the plasma osmo-
lality variation followed by blood pressure variations [16–
18]. AVP also suppresses nitric oxide (NO) production
[19]. The AVP release may also be suppressed by increased
levels of norepinephrine and the increased release of NO
from vascular endothelium of the posterior pituitary gland
[20, 21]. Terlipressin is a long-acting synthetic analogue of
AVP, proposed in the septic shock management as a rescue
therapy, when adequate MAP values are difficult to reach
with standard therapy. It is characterized by a longer duration
of action and a higher selectivity on the V
1
receptors that
limits the edemigenous effect mediated by the V
2
receptors
differently from what its native counterpart does [22]. AVP
and terlipressin can be both used with the aim of reaching the
desired MAP target or reducing the norepinephrine dosage
[23, 24].
In animal models in which severe uncontrolled blood
loss has been induced, the administration of AVP has shown
improvement in survival, neurologic outcome, and enhanced
hemodynamic performance [25–27]. During the irreversible
phase of hemorrhagic shock, unresponsive to fluids and
catecholamines administration, AVP can mediate peripheral
vasoconstriction through V
1
receptors [13, 28, 29]. AVP
works primarily on arterioles in extracerebral tissues, with
less constriction action on coronary and renal vessels with
potential vasodilatory effect on cerebral and pulmonary flow
[30]. Recent animal studies have shown that AVP treatment
can achieve hemodynamic optimization during prehospital
hemorrhagic shock, while fluids and catecholamines showed
neither improvement of hemodynamic parameters nor sur-
vival [1, 31, 32].
AVP use is associated with some adverse effects such
as ischemic complications especially in cardiac, splanchnic,
and skin circulation [33]. The decreased gut perfusion may
determine tissue necrosis with subsequent translocation of
bacteria that promotes the development of sepsis in the
postresuscitation phase [34]. The increased expression of the
V
1
receptor subtype in trauma brain injury might promote
the development of cerebral edema [8, 35].
To evaluate the impact on survival of V
1
receptor agonists
in hypovolemic refractory shock, we conducted a systematic
review and meta-analysis of data pooled from existing trials
comparing AVP or terlipressin and conventional shock man-
agement in mammals.
2. Materials and Methods
2.1. Search Strategy. All randomized animal trials using AVP
or terlipressin in hypovolemic shockwere identified. Relevant
studies were independently searched by two trained investi-
gators in Google Scholar and PubMed (updated November 4,
2013). The full PubMed search strategy, including keywords
AVP, arginine vasopressin, terlipressin, and hemorrhagic and
hypovolemic shock, was developed according to Biondi-
Zoccai et al. and is available in the Appendix [36].
2.2. Study Selection. References obtained from databases and
literature searches were first examined independently at the
title/abstract level by two investigators, with divergences
resolved by consensus and then, if potentially pertinent,
retrieved as a complete article.
Inclusion criteria for potentially relevant studies were
random allocation to treatment; animal experimental design;
comparison of AVP or terlipressin (with or without fluid
administration) versus placebo or fluids or catecholamines
or both fluids plus catecholamines. Exclusion criteria were
duplicate publications, human trials, and studies with no
data on survival. Two investigators selected studies for the
final analysis by independently assessing compliance to the
selection criteria.Divergences from the selection criteriawere
resolved by consensus.
2.3. Data Abstraction and Study Characteristics. Two inves-
tigators independently extracted data on the study design,
experimental setting, dosages of AVP or terlipressin, and
experimental duration, with divergences resolved by con-
sensus. If the required data could not be retrieved from the
published report, at least two separate attempts to contact the
original authors were made.
The primary end-point was mortality at the longest avail-
able follow-up. In addition, we performed further subanalysis
comparing animals treated with AVP (or terlipressin) with
those treated, respectively, with placebo, fluid resuscitation,
and other vasoconstrictive drugs.
2.4. Data Analysis and Synthesis. Computations were per-
formedwithRevMan 4.2 [35]. Binary outcomes from individ-
ual studies were analyzed to compute individual odds ratios
(ORs) with pertinent 95% confidence intervals (CIs), and
a pooled summary effect estimate was calculated by means
of the Mantel-Haenszel method and the fixed effect model
in case of low statistical inconsistency (𝐼2 < 25%) or the
random-effect model in case of moderate or high statistical
inconsistency (𝐼2 > 25%) [37]. Statistical heterogeneity and
inconsistency were measured using Cochran 𝑄 tests and
𝐼
2 (by Higgins and Thompson), respectively [38]. Statistical
significance was set at 2-tailed 0.05 for hypothesis testing and
at 0.10 for heterogeneity testing. According to Higgins et al.,
the 𝐼2 values around 25%, 50%, and 75% were considered to
represent, respectively, low, moderate, and severe statistical
inconsistency [38].
The risk of publication bias was assessed by visual
inspection of the funnel plot formortality. Sensitivity analyses
were performed by sequentially removing each study and
reanalysing the remaining dataset (producing a new analysis
for each study removed) and by analysing only data from
studies with low risk of bias.
3. Results
3.1. Study Characteristics. Database searches, backwards
snowballing, and contacts with experts yielded a total of
246 citations. After excluding nonpertinent titles or abstracts,
22 studies were retrieved in complete form and assessed
according to the selection criteria (Figure 1). Seven studies
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were further excluded for the absence of survival data. Fifteen
eligible trials were included in the final analysis.
The 15 included studies randomized 433 animals, 174 to
AVP (14 trials) or terlipressin (one trial) and 259 to control
(placebo, vasopressors, or fluid resuscitation). The included
trials were conducted on pigs (12 studies) and on rats (three
studies). All manuscripts were published in indexed journals.
Detailed study characteristics are summarized in Table 1.
3.2. Quantitative Data Synthesis. The overall analysis showed
that AVP/terlipressin were associated with a reduction in
animal mortality (26/174 (15%) in the AVP/terlipressin group
versus 164/259 (63%) in the control arms; OR = 0.09 (95%
CI 0.05–0.15); 𝑃 for effect < 0.001; 𝑃 for heterogeneity =
0.30; 𝐼2 = 14%) (Figure 2). When studies were grouped to
either fluid resuscitation, placebo, norepinephrine, or other
vasoconstrictive drugs as a comparator, administration of
AVP/terlipressin was still associated with a reduction in
mortality. (see Supplementary Figures 6(b)–6(e) available
online at http://dx.doi.org/10.1155/2014/421291).
Visual inspection of funnel plot identified an asym-
metrical shape, suggesting the presence of publication bias
(Figure 3). Sensitivity analyses performed by sequentially
removing each study and reanalysing the remaining dataset
(producing a new analysis for each study removed) did not
lead to major changes in direction or magnitude of statistical
findings. Sensitivity analyses carried out with studies with
low risk of bias (eliminating the studies responsible for
the asymmetry of the funnel plot) confirmed the overall
results of our work showing a reduction in mortality in
AVP/terlipressin animals versus controls (OR = 0.13 (95%
CI 0.08–0.24); 𝑃 for effect < 0.001, 𝑃 for heterogeneity
0.99, 𝐼2 = 0% with 10 studies and 329 animals included)
(Figures 4 and 5). Data of mortality are summarized in
Table 2.
In the majority of the studies included in this meta-
analysis, AVP has been administered with an initial bolus
followed by continuous infusion. Bolus doses ranged from
0.1 U/kg to 0.4U/kg while continuous infusion dosages
ranged from 0.04U/kg/min to 0.08U/kg/min. Other studies
report AVP infusion dosages in U/kg/h that range from 0.1
[21] to 2U/kg/h [39, 40]. In the study of Bayram et al.,
terlipressin was administered at the dose of 50mcg/kg [3].
4. Discussion
The most important finding of this meta-analysis is that the
use of AVP in the hypovolemic shock increases survival in
animal studies. All studies included were randomized (AVP
or terlipressin versus placebo, other vasopressors or fluid
administration), were conducted on animal models (pig and
rats), and were published in peer-reviewed journals.
The use of vasopressors in hypovolemic shock might
contradict the conventional knowledge of how to treat this
condition. Nevertheless their use in late phases of hem-
orrhagic shock is a common practice. Vasopressors have
recently been suggested in the European guidelines for the
management of hemorrhagic shock in order to maintain an
adequate mean arterial pressure when fluid therapy gives no
positive results [15, 41]. Guidelines recommend the use of
norepinephrine as the vasopressor of choice, whilst the use
of terlipressin or AVP is not mentioned.
The use of AVP and its synthetic analog terlipressin has
received significant attention in clinical practice, especially in
septic shock and cardiac arrest [43–46]. AVP was discovered
in 1895 from the extract of the posterior pituitary gland and
named after its vasoconstrictive properties [16, 42].
Landry et al. reported, for the first time, the successful
administration of exogenous AVP in patients with septic
shock [43]. Russell et al. compared the use of AVP versus
norepinephrine in patients with septic shock in the “Vaso-
pressin and Septic Shock Trial.”
In 779 patients the adverse effects were similar in both
groups, with no differences in 28-day mortality and major
organ dysfunction [44]. Another potential use of AVP is
in the pharmacological treatment of cardiac arrest [45, 46].
AVP followed by epinephrine may be more effective than
epinephrine alone in the treatment of refractory cardiac
arrest, especially in patients with asystole [29].
In recent years, several animal studies have shown that the
administration of AVP in patients with uncontrolled hemor-
rhagic shock is a promising treatment [10]. Our systematic
analysis of literature has evaluated several clinical studies on
animals. Morales et al. were the first ones to study the effects
of the administration of different doses of AVP (from 1 to
4mU/kg) in seven dogs undergoing prolonged hemorrhagic
shock and concluded that AVP is an effective agent in the
irreversible phase of hemorrhagic shock unresponsive to
volume replacement and catecholamines [28].
For a long time the use of vasopressors in hemorrhagic
shock was considered a debatable topic. During the early
phases of hemorrhagic shock arterial pressure is main-
tained as adequate through the activation of compensatory
vasoconstrictive mechanisms guaranteed by the sympathetic
system that produces a venous and arterial compensatory
vasoconstriction [41].
When blood loss is abundant and this mechanism is no
longer efficient to maintain an adequate organ perfusion,
the sympathetic system becomes inhibited with subsequent
reduction of peripheral resistance and bradycardia. Hemor-
rhagic shock is also responsible for an abnormal vascular
bed reaction mediated by nitric oxide that reduces the
response to endogenous and exogenous norephineprine [47].
The trauma and organ damage developing from the shock-
induced hypoperfusion bring about the activation of the
inflammatory cascade with subsequent vasoplegia [48, 49].
The use of vasopressors may be helpful in these cases. In
their retrospective study Plurad et al. determined that an early
vasopressor exposure after a critical injury is independently
associated with an increased mortality rate and this is not
related to the volemic status where hypovolemic patients are
those with values of central venous pressure ≤ 8mmHg. In
this retrospective study, vasopressor exposure was associated
with death independent of injury severity. Vasopressor-
treated patients had lower arterial pressure, required more
fluids and transfusions, and had a higher serum creatine [50].
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Figure 1: Flow diagram of the systematic review process.
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Figure 2: AVP or terlipressin versus all other strategies (fluid resuscitation, vasoconstrictors, and placebo).
However the update of the European guidelines has
recently considered the use of norepinephrine for irreversible
hemorrhagic shock.There are several human case reports that
have supported the use of AVP as an optimizing measure
capable of supporting arterial pressure during the triage of
trauma victims [27, 51].
At present, a multicenter, randomized controlled trial
(Vasopressin in Traumatic Hemorrhagic Shock—VITRIS
study) is being organized in Europe to evaluate the effects
of AVP in prehospital management of hemorrhagic shock
[52]. Unfortunately, as of now, we only have the results of
retrospective studies on humans. Collier et al. conducted
BioMed Research International 5
Table 1: Studies included in the meta-analysis.
1st author Journal Year Number of AVP (V) or terlipressin (T) Number of Controls Control Animal
Bayram [3] Am J Emerg Med 2012 7 (T) 14 Placebo (7);Ringer lactate (7) Rats
Cavus [31] Resuscitation 2009 8 (V) 8 Fluid resuscitation (8) Pigs
Cavus [55] Resuscitation 2010 8 (V) 16 Fluid resuscitation (8);noradrenaline + HS (8) Pigs
Dudkiewicz [56] Crit Care Med 2008 10 (V) 10 Phenylephrine (10) Pigs
Feinstein [8] J Am Coll Surg 2005 14 (V) 23
Crystalloid (9);
phenylephrine (5);
crystalloid +
phenylephrine (9)
Pigs
Feinstein [32] J Trauma 2005 8 (V) 9 NS (9) Pigs
Li [11] J Surg Res 2011 30 (V) 40
Placebo (10); Ringer
lactate (10); whole blood
(10); NE (10)
Rats
Liu [39] Shock 2013 32 (V) 48
Hypotensive
resuscitation (16);
Ringer lactate (16); NE
(16)
Rats
Meybohm [13] J Trauma 2007 7 (V) 7 HHS + NE (7) Pigs
Meybohm [57] Resuscitation 2008 10 (V) 20 Fluid (10); HHS + NS(10) Pigs
Raedler [10] Anesth Analg 2004 7 (V) 14 Saline placebo (7);fluid resuscitation (7) Pigs
Sanui [21] Crit Care Med 2006 5 (V) 5 Placebo (5) Pigs
Stadlbauer [30] Anesthesiology 2003 9 (V) 14 Saline placebo (7);fluid resuscitation (7) Pigs
Stadlbauer [40] Crit Care 2007 7 (V) 12 Saline placebo (5);fluid resuscitation (7) Pigs
Voelckel [1] Crit Care Med 2003 7 (V) 14 Epinephrine (7);saline placebo (7) Pigs
0
1
2
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4
5
SE
(lo
g[
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R]
)
0.01 0.1 1 10 100
OR
Figure 3: Funnel plot of comparison ofAVPor terlipressin versus all
other strategies (fluid resuscitation, vasoconstrictors, and placebo).
a retrospective cohort analysis of trauma patients requiring
vasopressors within 72 hours of admission. They observed
higher mortality (51% versus 41%) in patients treated with
AVP concluding that its administration is associated with
increased mortality in trauma patients with refractory
hypotension [53]. However patients treated with AVP in
this study have higher values of Trauma-Injury Severity
Score (TRISS) and initial lactate levels. Arterial blood
pressure values of these two groups are not reported.
Grmec et al. performed a prehospital prospective cohort
study to assess the influence of treatment with AVP and
hydroxyethyl starch solution (HHS) on outcome in resus-
citated blunt trauma patients with pulseless electrical activ-
ity (PEA) cardiac arrest. Thirty-one patients were stud-
ied concluding that victims of severe blunt trauma with
PEA should be initially treated with AVP in combination
with HHS for volume resuscitation followed by standard
resuscitation therapy and other procedures when needed
[54].
Studies conducted on animals have several limitations.
Survival timesmeasured in the experiments are different.The
median value is 15.5 hours and the median is 1.5 hours. Few
studies keep observing animals after six hours [11, 30]. Those
studies are performed with different protocols in settings
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Figure 4: Forest plot of comparison of AVP or terlipressin versus all other strategies including studies with low risk of bias.
Table 2: Results for mortality.
Outcome
Number of
included
trials
AVP/terlipressin
animals
Control
animals OR 95% CI 𝑃 for effect 𝑃 for heterogeneity 𝐼
2 (%)
Overall trials 15 174 259 0.09 0.05–0.15 <0.001 0.30 14
Mortality 15% 63%
Placebo as comparator drug 7 72 48 0.03 0.01–0.09 <0.001 0.57 0
Mortality 18% 92%
Fluid resuscitation as
comparator drug 11 114 117 0.08 0.04–0.15 <0.001 0.75 0
Mortality 18% 67%
Vasopressors (NE or
epinephrine) as comparator
drug
7 88 87 0.18 0.08–0.44 <0.001 0.96 0
Mortality 18% 39%
NE as comparator drug 4 54 53 0.16 0.06–0.45 <0.001 0.97 0
Mortality 20% 47%
Sensitivity analysis
(including only low risk of
bias studies)
10 134 195 0.13 0.08–0.24 <0.001 0.99 0
Mortality 18% 57%
varying from head trauma [55, 56], thoracic trauma, and
abdominal trauma [40] or after severe hepatic lesions [57].
Dosages used in animal trials are higher than dosages
used in human studies. Humans have been successfully
treated with AVP infusion of 2–4U/h in vasodilatory shock
[58, 59] and 10–20UI boluses in patients with upper intestinal
bleeding [60]. Most of the studies favorably estimate the
impact of AVP to handle hemodynamic and improve sur-
vival. However it is recommended not to underestimate the
possible adverse effects that might derive from the use of
AVP since its use is only indicated in irreversible shock no
longer treatable with fluid resuscitation alone. Vasopressin
could be considered as a possible pharmacologic adjunct in
patients with shock refractory to the administration of fluids
and catecholamines but the use of AVP alone cannot replace
the use of fluids [61]. The AVP, as well as other vasopressors,
seems to be beneficial only when administered in association
with fluids [62, 63].
5. Conclusions
Data acquired from our meta-analysis suggest strong scien-
tific evidence for the efficacy of AVP for the early treatment
of hemorrhagic shock in animal models. AVP has shown to
be more effective than all other treatments, including other
vasopressors drugs.We are awaiting the results of the VITRIS
BioMed Research International 7
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Figure 5: Funnel plot of comparison of AVP or terlipressin versus
all other strategies including studies with low risk of bias.
[50] study to confirm in humans the results obtained in
animal studies.
6. Methodological Limitations
Thepurposes, designs, and conduct are different between sys-
tematic review and meta-analysis of preclinical and clinical
studies. Clinical reviews are intrinsically confirmatory and
the aim of a Cochrane review is to provide evidence to allow
practitioners and patients to make informed decisions about
the delivery of health-care. Animal studies are meant to be
exploratory and do not lead to definitive conclusions directly
applicable to humans [64].
The results shown should be interpreted with caution.
Animal studies are inherently heterogeneous, more than
the typical clinical trials. Successfully translating findings
to human diseases depends largely upon understanding the
sources of heterogeneity and their impact on effect size [64].
The study is conducted without randomized controlled trials
in humans, and our findings should only be considered as
a hypothetical suggestion for further research, awaiting the
results of randomized controlled human trials.
Appendix
(“Vasopressin”[MeSH Terms] OR terlipressin[Text Word]
OR “arginine vasopressin”[Text Word]) AND (“hemor-
rhagic shock” OR trauma) AND ((randomized controlled
trial[pt] OR controlled clinical trial[pt] OR randomized
controlled trials[mh]OR randomallocation[mh]ORdouble-
blind method[mh] OR single-blind method[mh] OR clinical
trial[pt] OR clinical trials[mh] OR (“clinical trial”[tw] OR
((singl∗[tw] OR doubl∗[tw] OR trebl∗[tw] OR tripl∗[tw])
AND (mask∗[tw] OR blind[tw])) OR (“latin square”[tw]) OR
placebos[mh]ORplacebo∗[tw]OR random∗[tw]OR research
design[mh:noexp] OR comparative study[mh] OR evalua-
tion studies[mh] OR follow-up studies[mh] OR prospec-
tive studies[mh] OR crossover studies[mh] OR control∗[tw]
OR prospective∗[tw] OR volunteer∗[tw]) OR (animal[mh]
OR human[mh]) NOT (comment[pt] OR editorial[pt] OR
(meta-analysis[pt] NOT clinical trial[pt]) OR practice-
guideline[pt] OR review[pt]))).
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